0000950170-22-015246.txt : 20220808 0000950170-22-015246.hdr.sgml : 20220808 20220808072225 ACCESSION NUMBER: 0000950170-22-015246 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220808 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220808 DATE AS OF CHANGE: 20220808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CinCor Pharma, Inc. CENTRAL INDEX KEY: 0001868734 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41201 FILM NUMBER: 221142557 BUSINESS ADDRESS: STREET 1: 230 THIRD AVE., 6TH FLOOR CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 8445311834 MAIL ADDRESS: STREET 1: 230 THIRD AVE., 6TH FLOOR CITY: WALTHAM STATE: MA ZIP: 02451 8-K 1 cinc-20220808.htm 8-K 8-K







Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 08, 2022



CinCor Pharma, Inc.

(Exact name of Registrant as Specified in Its Charter)






(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)






230 Third Avenue

6th Floor


Waltham, Massachusetts



(Address of Principal Executive Offices)


(Zip Code)


Registrant’s Telephone Number, Including Area Code: 844 531-1834



(Former Name or Former Address, if Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class




Name of each exchange on which registered

Common Stock, $0.00001 par value per share




The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 2.02 Results of Operations and Financial Condition.

On August 8, 2022, CinCor Pharma, Inc. announced its financial results and general corporate updates for the second quarter ended June 30, 2022. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.


The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.





Press Release issued by CinCor Pharma, Inc., dated August 8, 2022



Cover Page Interactive Data File (embedded within the Inline XBRL document)




Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.




CinCor Pharma, Inc.






August 8, 2022


/s/ Mary Theresa Coelho




Mary Theresa Coelho, Executive Vice President, Chief Financial Officer and Chief Business Development Officer


EX-99.1 2 cinc-ex99_1.htm EX-99.1 EX-99.1


CinCor Reports Second Quarter Financial Results and Provides Corporate Update


Positive topline data in the Phase 2 BrigHtn trial, demonstrating clinically meaningful and statistically significant reduction in blood pressure with baxdrostat in treatment-resistant hypertension


Completed enrollment in the HALO Phase 2 trial for baxdrostat in patients with uncontrolled hypertension with 249 patients randomized; topline data expected in the second half of 2022


Initiated an Open Label Extension trial to evaluate the safety and tolerability of baxdrostat in patients for up to 52 weeks


Conference Call and Webcast Scheduled for 8:30 AM EDT Today


WALTHAM, August 8, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced financial results for the second quarter ended June 30, 2022 and provided a corporate update.


“We were very pleased to announce earlier today the positive topline data for baxdrostat in treatment-resistant hypertension. The CinCor team has continued strong execution across our clinical milestones this quarter, also announcing the completion of randomization in the Phase 2 HALO trial, initiation of a long-term extension trial in patients with uncontrolled hypertension and dosing the first patient in the Phase 2 figHTN-CKD trial,” said Marc de Garidel, Chief Executive Officer. “We look forward to continuing the clinical momentum with topline data for HALO expected to read out in the second half of 2022.”


Recent Corporate and Clinical Highlights

Positive Topline Phase 2 BrigHtn Trial Data. Earlier today, we reported positive topline data for the Phase 2 BrigHtn trial of baxdrostat for the treatment of patients with treatment-resistant hypertension (rHTN)
Successfully met the primary endpoint in the BrigHtn trial, delivering a 20.3 mmHg reduction in systolic blood pressure (SBP), or an 11 mmHg SBP (p-value < 0.0001) decline on a placebo-adjusted basis, at the 2 mg dose
Dose-dependent reductions observed in SBP
Compelling safety and tolerability profile with no drug related serious adverse events (SAEs) or major safety concerns reported across all three dose levels tested after 12 weeks of treatment
Phase 2 HALO Trial Completed Randomization. In July 2022, CinCor completed enrollment in the Phase 2 HALO trial with 249 patients randomized. HALO is a clinical trial


designed to evaluate the safety and efficacy of baxdrostat in patients with blood pressure that is not controlled despite treatment with up to two antihypertensive agents, referred to as uncontrolled hypertension (uHTN), and remains on track to report topline study results in the second half of 2022.
Phase 2 Open label extension (OLE) trial initiated, evaluating baxdrostat for up to 52-weeks in patients that previously participated in the Phase 2 HALO trial. Topline data from this trial is expected in the second half of 2023.
Dosed First Patient in the Phase 2 figHTN-CKD Trial. In June 2022, the first patient was dosed in the Phase 2 trial for baxdrostat in patients with uncontrolled hypertension and chronic kidney disease (CKD). Topline date from this trial is expected in the second half of 2023.

Key Anticipated Upcoming Milestones


Spark-PA: Phase 2 trial designed to evaluate the safety and efficacy of baxdrostat in patients with primary aldosteronism (PA)

Dosing of first patient expected in the third quarter of 2022
Topline data expected in the second half of 2023

HALO: Phase 2 trial designed to evaluate the safety and efficacy of baxdrostat in patients with uHTN

Topline data expected in the second half of 2022

figHTN-CKD: Phase 2 trial designed to evaluate the safety and efficacy of baxdrostat in patients with uHTN and CKD

Topline data expected in the second half of 2023


Second Quarter 2022 Financial Highlights


Cash Position: Cash, cash equivalents and marketable securities totaled $294.3 million as of June 30, 2022, as compared to $136.6 million as of December 31, 2021. The increase in cash, cash equivalents and marketable securities of $157.7 million was driven primarily by the Company’s January 2022 initial public offering (IPO) net proceeds of $193.6 million, partially offset by operating cash outflows of $37.3 million.


Research and Development (R&D) Expenses: R&D expenses for the three months ended June 30, 2022, were $17.2 million, compared to $4.0 million for the three months ended June 30, 2021. R&D expenses for the six months ended June 30, 2022, were $26.9 million, compared to $7.5 million for the six months ended June 30, 2021. The increase for the three and six month periods were primarily due to the progress of several Phase 2 clinical trials, including the full enrollment in our HALO trial, the initiation of our figHTN CKD and Open Label


Extension trials, increased chemistry, manufacturing, and controls spending, and the addition of several important full-time R&D resources.


General and Administrative (G&A) Expenses: G&A expenses were $4.2 million for the three months ended June 30, 2022, compared to $1.2 million for the three months ended June 30, 2021. G&A expenses were $8.2 million for the six months ended June 30, 2022, compared to $2.1 million for the six months ended June 30, 2021. The increases for three and six month periods were primarily attributable to increased personnel costs as we continued to build out our in-house team primarily based in Waltham, MA (reaching 21 employees by June 30, 2022), as well as increased legal and professional fees and other costs associated with operating as a public company.


Other Expenses: For the three months ended June 30, 2022 and 2021, CinCor incurred a non-cash expense of $0.0 million and $1.2 million, respectively, and $3.0 million and $2.4 million for the six months ended June 30, 2022 and 2021, respectively. The non-cash expense was related to the change in fair value of the Roche Warrants driven by an increase in the fair value of the underlying common stock. The Roche Warrants were automatically net exercised into common stock upon the completion of the IPO in January 2022.


Net Loss: For the three months ended June 30, 2022, CinCor reported a net loss of $21.1 million, compared to a net loss of $6.4 million for the three months ended June 30, 2021. Net loss for the six months ended June 30, 2022, was $37.8 million compared to a net loss of $12.0 million for the six months ended June 30, 2021.


About CinCor

CinCor, founded in 2018, is a clinical-stage biopharmaceutical company with a mission to bring innovation to the pharmaceutical treatment of cardio-renal diseases. Its lead asset, baxdrostat, a highly selective, oral small molecule inhibitor of aldosterone synthase, is in clinical development for the treatment of hypertension and primary aldosteronism.


About Baxdrostat (CIN-107)

Baxdrostat (CIN-107) is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland, in development for patient populations with significant unmet medical needs, including treatment-resistant hypertension and primary aldosteronism. Hypertension, which is defined by the American College of Cardiology and the American Heart Association as resting blood pressure above 130/80 mm Hg, is generally acknowledged to be one of the most common preventable risk factors for premature death worldwide. Though often asymptomatic, hypertension significantly increases the risk of heart disease, stroke, and kidney disease, amongst other diseases. It is estimated that as much as 20% of the global population suffers from hypertension, including nearly one-half of the adult population in the U.S., or 116 million hypertensive patients.


Forward-Looking Statements



This press release contains certain forward-looking statements, including, but not limited to, statements related to CinCor’s business in general; the results and timing of CinCor’s ongoing and planned clinical trials; the anticipated timing of disclosure of results of clinical trials; the progress of CinCor’s research and development programs and clinical trials and studies, including enrollment and retention in clinical trials; plans for initiating future clinical trials and studies; the therapeutic potential of baxdrostat (CIN-107); CinCor’s clinical milestones and pipeline; expectations with respect to regulatory matters; expectations with respect to potential market size; expectations relating to and the sufficiency of CinCor’s cash resources; and other statements that are not historical facts. Because such statements are subject to risks and uncertainties, actual results may differ from those expressed or implied by such forward-looking statements. Words such as “anticipates,” “believes,” “expected,” “intends,” “plan,” “may”, “will,” “project”, “estimate”, “continue,” “advance” and “future” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on CinCor’s current plans, objectives, estimates, expectations and intentions, involve assumptions that may never materialize or may prove to be incorrect and inherently involve significant risks and uncertainties, including factors beyond CinCor’s control, that could cause actual results, performance, or achievement to differ materially and adversely from those anticipated or implied in the statements, including, without limitation, CinCor has incurred significant operating losses since its inception; CinCor has a limited operating history and no history of commercializing products; CinCor will require substantial additional funding to finance its operations; CinCor’s business is entirely dependent at this time on the success of one drug, baxdrostat (CIN-107); interim, “top-line” and preliminary data from clinical trials announced or published from time to time may change; CinCor may not be successful in its efforts to expand its pipeline beyond baxdrostat (CIN-107); success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials; enrollment and retention of patients in clinical trials could be delayed; CinCor relies and will rely on third parties to conduct, supervise and monitor existing clinical trials and potential future clinical trials; developments from the company’s competitors and the marketplace for the company’s products; and CinCor’s business, operations and clinical development timelines and plans may be adversely affected by the evolving and ongoing COVID-19 pandemic, geopolitical events, including the ongoing military conflict between Russia and Ukraine and related sanctions, and macroeconomic conditions, including rising inflation and uncertain credit and financial markets, and matters related thereto; and other risks and uncertainties affecting the company, including those described under the caption “Risk Factors” and elsewhere in CinCor’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission (SEC) on March 22, 2022, CinCor’s Quarterly Report on Form 10-Q for the three months ended March 31, 2022 filed with the SEC on May 10, 2022, and other filings and reports that CinCor may file from time to time with the SEC, including its quarterly report on Form 10-Q for the three months ended June 30, 2022. Other risks and uncertainties of which CinCor is not currently aware may also affect the company’s forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. CinCor undertakes no obligation to publicly update


or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.



Contacts: Investors:
Terry Coelho Bob Yedid
CinCor Pharma, Inc. LifeSci Advisors
EVP, CFO and CBDO ir@CinCor.com


CinCor Pharma, Inc.

Condensed Statements of Operations

(In thousands, except share and per share amounts)





Three Months

Ended June 30


Six Months

Ended June 30









Operating expenses








Research and development

 $ 17,161


 $ 3,998


 $ 26,852


 $ 7,488

General and administrative








Total operating expenses








Loss from operations









Other (income) expense:








Interest income








Change in fair value of warrant derivative liabilities








Total other (income) expense, net









Net loss
















Net loss per common share, basic and diluted










Weighted average common shares outstanding, basic and diluted










CinCor Pharma, Inc.

Condensed Balance Sheet Data

(In thousands)










June 30,


December 31,









Cash, cash equivalents & marketable securities

$ 294,312


$ 136,606

Working capital








Total assets








Total stockholders’ equity (deficit)







GRAPHIC 3 img73281002_0.jpg GRAPHIC begin 644 img73281002_0.jpg M_]C_X 02D9)1@ ! 0 0 ! #_VP!# (! 0$! 0(! 0$" @(" @0# @(" M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_ MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H* M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P 1" !N &X# 2( A$! Q$!_\0 M'0 @(" P$ $&" (' P0%"?_$ #,0 $"!0,"!00" 00# M $" P $!1$Q!@=!$B$("1,R42)"4F$4P2,7&24G8W%R_\0 &@$! (# M 0 $" P0%"/_$ "X1 (! P,!!@4% 0 $" ,$ M$1(A,043(D%1<9$'(S)AL0@40F+1\/_: P# 0 "$0,1 #\ ^^@"NWT\?E# M5?V\C[H03C&/B&$]^,CB$165;V\?E^X9"K^WD_="Z>W&/C]PRGOQD\0B "K^ MWD?="LJWMX_+]PPGOQD<0NGMQCX_<(@H*N?IY_* !5C]/'Y0*3W.,_$ 3V., M?$(C(5?V\G[H %7]O(^Z I[\9/$ 3WXR.(1%95O;Q^7[AD*O[>3]T+I[<8^/ MW#*>_&3Q"( *O[>1]T*RK>WG\H83WXR.(73VXS\0B )[=^/B&";YY'$,7[=E M8_. 7OA61]\(F-S;/'Q^X9)OGD\0^]L*Q^?[@-[X5D_?"(@3?/(XA7-L\?'[ MC(7OA61]\'>V%8_/]PB8J)N>_/Q ";'OQ\0U7N>RL_G +V/96/SA$"3?/)X@ M!-\\CB&;WPK)^^ 7OA61]\(F-S;/'Q^X9)OGD\0^]L*Q^?[@-[X5D_?"(@3? M/(XA7-L\_$9"]\*R/OA=[85G\X1$$XQCXAA/?C(XB-;I[M[8[':'G=S=XMPZ M-I;3U.2#/5JOU%N5EF>H]*4E;A ZE*(2E(NI2B 20(U#1_-*\"E8JDA2YC? M15%%5F$,4RHZLTK5J)3YMU79"&YV?E69=94>R0'/J)%KW$9Z5I>5T+4J;,!X M@$CW E2RKR<2P73VXQ\?N&4]^,GB(YN?NGH'9?;JK;K[I:IEJ+IVA2"IRKU6 M:ZBW*L)M=Q72"2.XP#F%NMNWMSL;MO5]W]V]82=!TS09(S=8K,^I09E& 0"X ML@$@74.]N8Q*E1B %)R<#;D[;#S.X]Y.1)($]^,CB%T]N,?'[CKTFKTVN4R7 MK5%J+$Y)S;#;\I-RKH<:?:6D*0M"TDA25)((([$$$1X]9W-T-0-?43:ZL:GE MI?4&I)&?G*'2G"KU9QB2+/\ *<186LW_ "6+W(/^06OWB KDX R?\Y]O&3D2 M0*3W.,_$ 3V.,?$=#4FIM.:-H$]JW6&H9&DTJG2RYFHU.IS:)>7E&$#J6ZZZ MX0EM"0"2I1 S&@AYL/@"+8J!W^Z*27.@:H*H93^$4?^3UNCF\ M9J%I=W()HTV;'. 3CV!E6=5Y.)8TI[\9/$ 3WXR.(Z%"U%0]4T64U-IBMR=1 MIM0EDS$A4*?-)>8F65I"D.-N()2M"@00H$@@QI/Q*^97X.O"=JE6@]W]VDHU M&AA#[^G:)39BHSDLTH I6\B70H, @@@.%)(4" 0;QIUJU&V0O58*!R2$WQ@ M*53-C=X)*=K#3!=F-.3Z%R=290,J,NZ I:1RI'4D7%R(GV\^^.U?AVVXF]V- MZM;2U T_(/L,S53FT.+2EQ]Y#+* EM*E*4MQQ" "25"+T'2Z -$Z\\:=\^F M)7J?3.I=%NVM>H47HU5Y5U*,/4, ?3SDN">_&1Q"Z>W&?B*XI\VSR\RL(>\2 MDA+IN.M^=H=28:;'RMQR62A ^5*( Y,;XT3KK1NY.DI#7>WFKJ77J)5&/7IE M8HL^W-2LVT38+:=;*D.)['N"<1M5[2[M5!K4V4'S!'Y G/5T<]TYE:-OM'4K MQ8>83N)N5NE*MU6@[ U2GZ7VUH4TGKE92MOTUBHU*M*:5=*IOHG9:4:<(NRV MR[T=)>639O5VD-+Z\TS/:,UOIV2K%(JDNJ7J5+JLJB8EIIE0LIMQMP%*TGD$ M$15S6VK7/ !XN-;[Y;DR$TG9G>%-/J%>U7)2#DPUHW4LI*HD2Y/H:2I34A.2 MK,J!-6*&7V%!TH2Z%QL377F3^!#0NED:H=\5FAZV9GI%*H^D*\Q6JG5G%=D, MRZKO2>W4LFE0ND$X( U#;@ZLD_^9;MCH797RA=TMIMK]/HI&GM.[8O2-%IC+JUHE)9LH2AM*EJ M4HA(["Y)M'O^;G<>7#N4" 0JER"5)6D*2H&HR@((/8@BX(/8@V,1SS+=>0A IM.NI1L!_P E)CF-OIQ?M+/6.=]_&4?!+ M>6G_ &>=MI,S'EZ[U2'AMK[SIV7U[65,[1U=]7TZ1K#I4M6F7EDV$J\KJ^A/^Y;X>;W'_ %YN)<'_ .M/QN/>?9W;S?\ VQK^SFZNGFZK MI[44FJ4JQ%NUL6BL_BAE=7^&?Q44+QZ4+254U#H^8T M8=';NTZ@T]R;GZ93VYIHE*O2(B83'F3>7 MY+Z$_P!1W/&GM>:49?UD.-ZRE%O+[7]-,NE9>4[QZ(07"KZ>GJ[1IW-"O7H4 M3;J60*!L"<-OJ!QXD[C^N/*7!"DZIQ;HL[&^75X1];:MVFTS2=&4:F(J-4D9 M"3ES_#15YUP^F4M7*6T+FG$?XT (3K$TI*6P^HW*DH>67'6VR ?\ *;VZ03]$M9TNF^95X*=8:*F= M!:HT52M:R4Y):>=UC21)SC[3:TJDZH94J+K#+CB$N(:?2V_Z8!6V@J BBLFF M:J5!5X8_%7HN0TMKJAR/\*8H%195+T^K2DJA(;G).:=*6'4J"00I#@*3:X21 M'G'X\T.M5;:W0T7JT-?S0A);T.,\[;^!$]&_!>MT1.AW"-EJAJJ:RA@":"J" MI QNH?7K))5#H) R#.K6ZM1O$MLLC=':R8=IVO-.2:JYH34M,DE?S9*HL N^ M@2VD**7 @M*2JX5U6-^P-O?&CN)4]Q_ 9MQNCJK34]IJ;JNYVVE1JM*KS/\ M%?IBU:GI:W4/)7T^ET$*OU6L!Q% =Q=X6Z%IV;\(GA=IU4U'N5J=+E-EZ3HY M;+QILJZM!<*GY99;]3HLDJ2KH;'4M:TGM%R/$#M_N;IORLML]J/%G2J1,Z@: MW.V[H^II(SQJ,M.LC5=-82AU;W4'U.2X1ZH-TJ4I>08WOTYV74;"[JTZRU$H M&JI17'T@$9YXSY?8GC$M\<>G4[;H%M6[J@U'[)&/S>R902P&Q[(L!@XTZLE= MG.;@5??S8ND4V;K%7WKTG*R4FTIV=1 MU)]XB?*U\(^[&VLU0-L=C=![>ZLD)QBJ:/UGIO0M/:?I%5EE^I+/+0EH M)F6.L=+LNNZ'6E+2;$A0E7@U\3SV_>D*IHO<32TKI;=#;^=11]S-$,N=8I<[ MT=34Q+W[N2$RU9^6>PIM722%MK2GT$#;4^FU&MR6U8#!L#2,@AL G.2,9_CP M1WA/-_?-0:IN=QD.I*' %)*2"#@CX/S$?TUL_M3HVMNZDT?MEIVDU&8)]>?I ME$EY=]SJSU.-H"C?FY[Q) %=NRL0 *OA61')5F4$ G>9, SAFJ?)STHJ1GI5 MMYA:.E;+J I"A?!!%B()N0E)^75*3TJV\TL66TZ@*2JW?N"+&.:RK85C^X"% M7PK)B!M)B2BW:^3WCB;V?VI:U8=>M;8Z=37>KJ-:%$EQ-WQ?U@CKO M^[Q(U!5SV5F !5CV5B+*63Z3B1@3%3)-[*-S>YO'2KNEZ!JBENT/4M$DZC)3 M">A^3GY9#S3B3D*0L%)'Z(CT"%7PK)@ 5?"LB*X&,2RLR.&4X(X/B)$]N-B= MF-G6GV=H]I-,:61,V_DIT[09>2]7OA7HH3U?^C$FF:?)SK08G95MY"7 M*74 M!0"DD%*K$9! (/!$FTRU[BXNJIJUW+L>2Q)/N M8NGMTD_$<+=-D6IM=1:DVD3#J$H=?0@!:TIOTI*K7(%S8'%S'. J^%9$*RK8 M5F+3#&.GMV1CY@'3?",CF ]NYQ ;Y.1"(?3;",?/[@/3?",GF"QMDX_N @ MWRT9^81/_V0$! end EX-101.LAB 4 cinc-20220808_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications EX-101.SCH 5 cinc-20220808.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 6 cinc-20220808_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document And Entity Information
Aug. 08, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 08, 2022
Entity Registrant Name CinCor Pharma, Inc.
Entity Central Index Key 0001868734
Entity Emerging Growth Company true
Entity File Number 001-41201
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 36-4931245
Entity Address, Address Line One 230 Third Avenue
Entity Address, Address Line Two 6th Floor
Entity Address, City or Town Waltham
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02451
City Area Code 844
Local Phone Number 531-1834
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period true
Title of 12(b) Security Common Stock, $0.00001 par value per share
Trading Symbol CINC
Security Exchange Name NASDAQ
XML 8 cinc-20220808_htm.xml IDEA: XBRL DOCUMENT 0001868734 2022-08-08 2022-08-08 0001868734 false 8-K 2022-08-08 CinCor Pharma, Inc. DE 001-41201 36-4931245 230 Third Avenue 6th Floor Waltham MA 02451 844 531-1834 false false false false Common Stock, $0.00001 par value per share CINC NASDAQ true true EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://cincor.com/20220808/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports cinc-20220808.htm cinc-20220808.xsd cinc-20220808_lab.xml cinc-20220808_pre.xml cinc-ex99_1.htm http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cinc-20220808.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "cinc-20220808.htm" ] }, "labelLink": { "local": [ "cinc-20220808_lab.xml" ] }, "presentationLink": { "local": [ "cinc-20220808_pre.xml" ] }, "schema": { "local": [ "cinc-20220808.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cinc", "nsuri": "http://cincor.com/20220808", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "cinc-20220808.htm", "contextRef": "C_9e392a8a-1926-490d-b95b-217921618822", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "role": "http://cincor.com/20220808/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "cinc-20220808.htm", "contextRef": "C_9e392a8a-1926-490d-b95b-217921618822", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cincor.com/20220808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cincor.com/20220808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cincor.com/20220808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cincor.com/20220808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cincor.com/20220808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cincor.com/20220808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cincor.com/20220808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cincor.com/20220808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cincor.com/20220808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cincor.com/20220808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cincor.com/20220808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cincor.com/20220808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cincor.com/20220808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cincor.com/20220808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cincor.com/20220808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cincor.com/20220808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cincor.com/20220808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cincor.com/20220808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cincor.com/20220808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cincor.com/20220808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cincor.com/20220808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cincor.com/20220808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cincor.com/20220808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cincor.com/20220808/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0000950170-22-015246-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-22-015246-xbrl.zip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end